Table 2 PSP plasma levels in COVID-19 ICU patients: it shows differences between survivors and non-survivors for PSP plasma level each time points with Wilcoxon sign rank test, Two-way ANOVA during the time, mixed model coefficients, and Area Under the Receiving Operator sensitivity and specificity for the primary outcome
From: Point-of-care pancreatic stone protein measurement in critically ill COVID-19 patients
PSP ng/ml | T0 (21 patients survived) | T1 (21 patients survived) | T2 (21 patients survived) | T3 (21 patients survived) |
|---|---|---|---|---|
Survivors (mean ± st. dev) | 105.53 ± 28.53 | 157.76 ± 90.26 | 102.66 ± 66.94 | 155.25 ± 119.85 |
Nonsurvivors (mean ± st. dev) | 214.87 ± 134.60 | 359.75 ± 249.85 | 399.00 ± 215.15 | 352.5 ± 119.81 |
p | 0.0098* | 0.0148* | 0.0003* | 0.0048* |
|  |  |  | Two-way ANOVA | P < 0.001 |
| Â | PSP | Mortality | Timing | Cons |
Correlation coefficients (Rrm) | 210.76 | 204.94 | 11.93 | 86.67 |
P |  < 0.001* |  < 0.001* | 0.042* | 0.003* |
| Â | T0 | T1 | T2 | T3 |
AUROC | 0.821 | 0.7019 | 0.9271 | 0.9062 |
P value | 0.048 | 0.030 | 0.036 | 0.012 |
Sensitivity | 62.50% | 50.00% | 75.00% | 62.50% |
Specificity | 100.00% | 92.31% | 91.67% | 91.67% |
Positive predictive value | 100.00% | 80.00% | 85.71% | 83.33% |
Negative predictive value | 81.25% | 75.00% | 84.62% | 78.57% |
Correctly classified | 85.71% | 76.19% | 85.00% | 80.00% |